These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. Gomez E; Garcia Buey L; Molina E; Casado M; Conde I; Berenguer M; Jorquera F; Simón MA; Olveira A; Hernández-Guerra M; Mesquita M; Presa J; Costa-Moreira P; Macedo G; Arenas JI; Manuel Sousa J; Ampuero J; Morillas RM; Santos A; De Carvalho A; Uriz J; Carrión JA; Luisa Gutiérrez M; Pérez-Fernández E; Fernández-Rodríguez CM; Aliment Pharmacol Ther; 2021 Feb; 53(4):519-530. PubMed ID: 33314220 [TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid for the treatment of primary biliary cholangitis. Ali AH; Lindor KD Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review. Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis. Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778 [TBL] [Abstract][Full Text] [Related]
16. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. Carbone M; Harms MH; Lammers WJ; Marmon T; Pencek R; MacConell L; Shapiro D; Jones DE; Mells GF; Hansen BE Hepatol Commun; 2018 Jun; 2(6):683-692. PubMed ID: 29881820 [TBL] [Abstract][Full Text] [Related]
17. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D; N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829 [TBL] [Abstract][Full Text] [Related]
18. Obeticholic acid-a new therapy in PBC and NASH. Chapman RW; Lynch KD Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030 [TBL] [Abstract][Full Text] [Related]
19. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590 [TBL] [Abstract][Full Text] [Related]
20. Management of primary biliary cholangitis prior to obeticholic acid availability. Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]